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Abstract
Robust optimization generates scenario-based plans by a minimax optimization method
to find optimal scenario for the trade-off between target coverage robustness and
organ-at-risk (OAR) sparing. In this study, 20 lung cancer patients with tumors located
at various anatomical regions within the lungs were selected and robust optimization
photon treatment plans including intensity modulated radiotherapy (IMRT) and volumet-
ric modulated arc therapy (VMAT) plans were generated. The plan robustness was ana-
lyzed using perturbed doses with setup error boundary of 3 mm in anterior/posterior
(AP), 3 mm in left/right (LR), and 5 mm in inferior/superior (IS) directions from
isocenter. Perturbed doses for D99, D98, and D95 were computed from six shifted
isocenter plans to evaluate plan robustness. Dosimetric study was performed to
compare the internal target volume-based robust optimization plans (ITV-IMRT and
ITV-VMAT) and conventional PTV margin-based plans (PTV-IMRT and PTV-VMAT).
The dosimetric comparison parameters were: ITV target mean dose (Dmean), R95(D95/
Dprescription), Paddick’s conformity index (CI), homogeneity index (HI), monitor unit (MU),
and OAR doses including lung (Dmean, V20 Gy and V15 Gy), chest wall, heart, esophagus,
and maximum cord doses. A comparison of optimization results showed the robust opti-
mization plan had better ITV dose coverage, better CI, worse HI, and lower OAR doses
than conventional PTV margin-based plans. Plan robustness evaluation showed that the
perturbed doses of D99, D98, and D95 were all satisfied at least 99% of the ITV to
received 95% of prescription doses. It was also observed that PTV margin-based plans
had higher MU than robust optimization plans. The results also showed robust optimiza-
tion can generate plans that offer increased OAR sparing, especially for normal lungs
and OARs near or abutting the target. Weak correlation was found between normal lung
dose and target size, and no other correlation was observed in this study.
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1 | INTRODUCTION
Robust optimization is primarily used to plan intensity modulated
proton therapy (IMPT) 1 and it was not until recently that robust
optimization techniques have been available for x-ray beam in radia-
tion therapy treatment planning system.2 Robust optimization meth-
ods have been used in radiation therapy to account for position
uncertainties relative to the target volume during treatment delivery.
Position uncertainties come from two sources: tumor motion and
variations in tumor shapes, and patient setup uncertainties. One way
to approach these uncertainties is to use minimax optimization.3
Instead of expanding the internal target volume (ITV) with a fixed
margin to create the planning target volume (PTV), robust optimiza-
tion allows entering the setup uncertainties into the planning com-
puter and discretizes them into multiple scenarios (shifts within the
margin bounds). The minimax optimization method minimizes
the objective function such that the prescription holds true even in
the worst case scenario. That is, robust optimization method gener-
ates scenario-based plans that have plan quality considered at least
equivalent to static PTV margin-based plans.4–6 This method has the
potential to reduce the doses to healthy tissues, especially for
tumors with substantially larger intrafraction motions in which there
could be overlap between PTV and organ at risk (OAR).
The purpose of this study was to investigate the use of RaySta-
tion (v.5.4, RaySearch Laboratories, Sweden) photon robust optimiza-
tion method for planning lung cancer patients. Both robust-
optimized intensity modulated radiotherapy plans (ITV-IMRT) and
robust-optimized volumetric modulated arc therapy plans (ITV-
VMAT) were evaluated. A dosimetric study was performed to com-
pare robust optimization plans with the corresponding traditional
PTV margin-based plans (PTV-IMRT and PTV-VMAT). A correlation
study was also performed to investigate the relationship between
the target mean dose and the tumor size or tumor motion and the
relationship between normal lung dose and tumor size or tumor
motion.
2 | MATERIALS AND METHODS
2.A | Patient characteristics
Twenty lung cancer patients who were previously treated in our
clinic were selected. Tumors located at various anatomical regions
within the lungs were selected (11 in upper lobe, 8 in lower lobe,
and 1 in middle lobe). Among these, 4 were centrally located and 16
were peripherally located according to the definition of peripheral or
central tumor location defined in RTOG 0915.7 The median ITV vol-
ume was 10.39 cc (3.29–107.23 cc) and the median PTV volume
was 38.57 cc (19.12–210.23 cc). The tumor motion was determined
by measuring the largest shifted distance from the center of tumor
mass in the inferior–superior (IS), left–right (LR), and anterior–poste-
rior (AP) directions. The isocenter was placed automatically at the
center of tumor mass during treatment planning and the tumor
motion was measured based on 4D-CT volume image set. The
median maximum tumor motion within 3D mobility vectors was
1.45 cm (0.54–3.4 cm). The patient characteristic details are listed in
Table 1.
2.B | ITV and PTV contour generation
To account for potential lung tumor motion for each patient, four-
dimensional CT (4DCT) images with ten respiratory phases (0% to
90%) were acquired on a CT-simulator (Brilliance CT Big Bore, Phi-
lips, Cleveland, OH, USA) for each patient and imported to the RayS-
tation treatment planning system (TPS). Ten gross tumor volumes
(GTV) corresponding to different phase image datasets (GTV 0% to
GTV 90%) were identified and manually delineated by the treating
radiation oncologist. A single planning ITV contour was then created
by encompassing all ten-phases of GTVs. The PTV contour was gen-
erated by extending the ITV contour to 0.5 cm in LR and AP direc-
tion and 1.0 cm along IS direction.
The robust treatment plans were generated based on all ten res-
piratory phases of the CT image datasets to evaluate the plan
robustness caused by the tumor motion. Plan comparison between
robust optimization and PTV margin-based optimization was per-
formed using treatment plans generated based on the 20% phase of
the CT image dataset.
TAB L E 1 Patient characteristics.
Patient # ITV (cc) PTV (cc)
Tumor a
location
Tumor
motion (cm)
1 43.99 126.26 LUL-p 0.60
2 8.52 31.40 RUL-p 2.59
3 5.69 23.84 LLL-p 2.50
4 17.90 53.34 RUL-c 3.07
5 28.03 78.61 RUL-c 3.40
6 6.13 24.18 LUL- p 2.12
7 10.40 41.01 RLL-p 2.64
8 3.29 19.12 LUL-p 1.00
9 45.59 111.36 RLL-p 2.4
10 9.90 33.26 LLL-p 1.45
11 9.88 35.23 RUL-c 0.70
12 10.37 36.12 LLL-p 2.00
13 3.88 21.40 LUL-p 0.70
14 25.20 67.55 RUL-p 1.07
15 26.20 82.20 LUL-p 0.54
16 7.05 30.70 LLL-p 1.15
17 6.28 27.50 RUL-p 1.20
18 18.69 66.78 RML-p 1.00
19 107.23 210.23 RLL-c 1.87
20 38.38 94.23 LLL-p 2.37
Median
(range)
10.39
(3.29–107.23)
38.57
(19.12–210.23)
1.45
(0.54–3.4)
aLUL, left upper lobe; LLL, left lower lobe; RUL, right upper lobe, RML,
right middle lobe; RLL, right lower lobe, c, central; p, peripheral.
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2.C | ITV robust optimization plan and PTV margin-
based plan
ITV robust optimization plans were generated using minimax opti-
mization method by minimizing the penalty of the worst case sce-
nario. The minimax method does not minimize the worst of all
possible scenarios, but the worst scenario within some predefined
range. It considers only scenarios that are physically reliable; with
unnecessary conservative case scenarios being avoided.3,4 The range
of patient setup error specified by the user was 0.5 cm in LR,
1.0 cm in IS, and 0.5 cm in AP direction for this study. This range of
uncertainty was selected based on RTOG 0236 and 0915 proto-
cols.8,9 The total numbers of scenarios considered in the minimax
optimization are related to the size of the uncertainty range speci-
fied in the TPS. In this study, a total of seventeen scenarios were
generated based on the selected uncertainty.
Four treatment plans were generated per patient, among them
two plans were robust optimization plans (ITV-IMRT and ITV-VMAT)
and two plans were PTV margin-based plans (PTV-IMRT and PTV-
VMAT). For comparison purposes, the planning and optimization
parameters were kept identical for all plans except those in ITV opti-
mization-based plans where the robust optimization function was
used. The prescription dose (Dp) was such that at least 95% of the
ITV or PTV receives 60 Gy in eight fractions. The lung doses were
constrained as V20 Gy<20% and V15 Gy<37%.
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2.D | Plan evaluation
Plan robustness was evaluated by calculating perturbed doses from
multiple spatially shifted 3D vectors in both positive and negative
directions. The shifted values from isocenter were 3 mm in AP direc-
tion (0, 0, 3), 3 mm in LR direction (3, 0, 0), and 5 mm in SI direc-
tion (0, 5, 0). A total of six perturbed dose distributions were
computed for each plan. Evaluation metrics included perturbed doses
of D99 (isodose that cover 99% of ITV), D98 (isodose that cover 98%
of the ITV), and D95 (isodose that cover 95% of the ITV). The per-
turbed doses were computed for each of the six shifted isocenter
plans.
Other dosimetric comparisons and evaluations performed for
both robust optimization and conventional margin-based plans
included: ITV target mean dose (Dmean), R95 (D95/Dp), Paddick’s
conformity index, homogeneity index, MU, and OAR doses including
normal lung (Dmean,V20 Gy and V15 Gy), chest wall, heart, esophagus,
and maximum cord doses. The Paddick’s conformity index (CI) is cal-
culated based on the following equation:
CI ¼ TV
2
PIV
TV  VPIV
Where TV is the target volume, TVPIV is the target volume covered
by the prescription isodose volume (PIV), and VPIV is the total pre-
scription isodose volume. The homogeneity index (HI) is calculated
based on the following equation:
HI ¼ D2%  D98%
Dp
Where Dp is the prescription dose.
2.E | Statistics
A multivariate ANOVA statistical test11 was performed to compare
the statistical difference between multigroup treatment plans (ITV-
IMRT, ITV-VMAT, PTV-IMRT, and PTV-VMAT). For the robust
optimization plans, a Student t-test was performed to compare the
pairwise difference between two treatment techniques (ITV-IMRT
and ITV-VMAT) for robust optimization plans.12 A P-value <0.05 was
considered statistically significant. A study was performed using a
linear model with SigmaPlot software version (v.13, Systat Software,
Inc., San Jose, CA, USA, www.systatsoftware.com) to evaluate the
correlation between the target mean dose and the perturbed dose
of D99, D98, and D95 versus the tumor size/tumor motion. Similarly,
a study was performed to evaluate the correlation between the nor-
mal lung tissue doses versus the tumor size, and tumor motion. In
addition, correlation was estimated between ITV mean dose and
tumor size, tumor motion.
3 | RESULTS
3.A | Target dose evaluation
The median and ranges of target mean doses (Dmean), target cover-
age (R95), HI, CI, and MU from robust optimization and PTV margin-
based plans using both IMRT and VMAT treatment techniques are
shown in Table 2.
Table 2 shows that the ITV target dose coverage satisfied the
prescription requirement for both robust optimization and PTV mar-
gin-based plans. In addition, the robust optimization plans showed
better CI and worse HI compared to PTV margin-based plans. Fig-
ure 1 shows examples of ITV DVHs for three patients with different
tumor sizes and tumor motion distances for robust optimization
(solid line) and PTV margin-based (dotted line) IMRT and VMAT
plans.
The differences between the IMRT and VMAT technique using
robust optimization method were compared and the results are
shown in Table 3 and Fig. 1. It was observed that there was no sta-
tistical difference for ITV dose coverage and that there was a statis-
tically significant difference with better HI and CI for ITV-IMRT
compared to ITV-VMAT plans.
Perturbed doses were calculated to evaluate plan robustness.
ITV perturbed median doses and ranges of D99, D98, and D95 calcu-
lated from six shifted isocenter plans are shown in Tables 4–6.
Results show that the ITV perturbed doses of D99, D98 and D95
were covered at least more than 95%, 96%, and 98.5% of the pre-
scribed dose for all six shifted isocenter plans.
A Student t-test was performed to compare the difference
between IMRT and VMAT treatment techniques for the plans using
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robust optimization methods (ITV-IMRT vs. ITV-VMAT). For the per-
turbed doses of D99 and D98, the results showed statistically signifi-
cant differences between ITV-IMRT and ITV-VMAT plans in a
majority of shifted points where ITV-IMRT perturbed dose coverage
was better than the coverage of ITV-VMAT plans. For the perturbed
doses of D95, except in IS direction, there was no statistical
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F I G . 1 . ITV DVHs for robust-optimized IMRT plan (solid red line), robust-optimized VMAT plans (solid green line), PTV margin-based IMRT
plan (dotted red line), and PTV margin-based VMAT plan (dotted green line). (a) Pt8, max target motion d = 1 cm, ITV = 3.29 cc. (b) Pt19, max
target motion d = 1.87 cm, ITV = 107.23 cc. (c) Pt5, max target motion d = 3.4 cm, ITV = 28.03 cc.
TAB L E 3 Median and ranges of Dmean, R95, HI, CI, and MU for ITV target from robust optimization plans.
Dmean(Gy) R95 HI CI MU
ITV-IMRTa 61.85 (61.05–66.43) 1.00 (0.99–1.01) 0.073 (0.034–0.205) 0.60 (0.31–0.82) 1365 (1091–2691)
ITV-VMATb 64.44 (61.32–67.11) 1.00 (1.00–1.00) 0.124 (0.042–0.246) 0.57 (0.32–0.76) 1200 (1046–1867)
Student t-test significant? Yes P < 0.001 No P > 0.05 Yes P < 0.001 Yes P = 0.004 Yes P = 0.003
arobust optimization ITV-IMRT plan.
brobust optimization ITV-VMAT plan.
TAB L E 2 Median and ranges of Dmean, R95, HI, CI, and MU for ITV target using IMRT and VMAT technique.
IMRT VMAT
ITV robusta PTV nonrobustb
ANOVA test
Significant? ITV robusta PTV nonrobustb
ANOVA test
Significant?
Dmean (Gy) 61.85 (61.05–66.43) 62.76 (61.21–83.3) Yes P = 0.012 64.44 (61.32–67.11) 65.77 (63.14–82.48) Yes P = 0.002
R95 1.00 (0.99–1.01) 1.03 (1.01–1.32) Yes P < 0.001 1.00 (1.00–1.00) 1.06 (1.03–1.29) Yes P < 0.001
HI 0.073 (0.034–0.205) 0.040 (0.022–0.163) Yes P < 0.001 0.124 (0.042–0.246) 0.069 (0.04–0.206) Yes P < 0.001
CI 0.60 (0.31–0.82) 0.26 (0.03–0.50) Yes P < 0.001 0.57 (0.32–0.76) 0.26 (0.12–0.50) Yes P < 0.001
MU 1365 (1091–2691) 1844 (1188–2960) Yes P < 0.001 1200 (1046–1867) 1503 (1124–2194) Yes P < 0.001
aITV-based robust optimization plans.
bPTV margin-based optimization plans.
TAB L E 4 ITV perturbed doses of D99 (Gy).
D (mm)a (3,0,0) (3,0,0) (0,5,0) (0,5,0) (0,0,3) (0,0,3)
ITV-IMRT 58.57 (49.58–59.68) 58.38 (50.44–59.56) 57.93 (50.81–59.42) 58.18 (51.74-59.14) 58.28 (48.05-59.70) 58.61 (50.98-59.29)
ITV-VMAT 57.15 (49.81–59.68) 56.81 (50.51–59.49) 56.66 (50.40–59.42) 57.03 (50.01-58.80) 56.97 (47.26-59.48) 57.08 (51.1-59.05)
Student t-test
significant?
No P > 0.05 Yes P = 0.016 Yes P = 0.002 Yes P = 0.002 Yes P = 0.008 Yes P = 0.028
ashifted distance in mm from isocenter in (x, y, z) direction.
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difference between all shifted plans. A statistical correlation test was
performed and no correlation was observed between the perturbed
doses (D99, D98, and D95) and the tumor volume, tumor motion.
3.B | OAR doses
The median mean doses and ranges for lung, heart, esophagus, and
median maximum doses and ranges for spinal cord from robust opti-
mization and PTV margin-based plans using IMRT and VMAT treat-
ment techniques are shown in Table 7. Results showed statistically
significant differences between robust optimization and PTV margin-
based plans. The robust optimization plans showed lower OARs
doses compared to PTV margin-based plans.
Similar results of OAR doses for robust optimization (ITV-IMRT
and ITV-VMAT) plans are shown in Table 8 and results showed no
statistically significant differences between robust optimization ITV-
IMRT and ITV-VMAT plans.
A statistical correlation study was performed to evaluate the cor-
relation between the normal lung tissue dose and tumor volume
size/tumor motion, and results showed weak correction with the
tumor volume size (r2 = 0.138 for ITV-IMRT plans, r2 = 0.110 PTV-
IMRT plans, r2 = 0.255 for ITV-VMAT plans, and r2 = 0.048 for
PTV-VMAT plans). Normal lung tissue dose showed a better correla-
tion with tumor volume for robust optimization plans compared to
PTV margin-based plans. No correlation was found between normal
lung tissue dose and tumor motion in this study.
4 | DISCUSSION
The main goal of this study was to investigate the photon robust
optimization method for lung cancer patient and to evaluate the plan
robustness with perturbed doses shifted from isocenter. In addition,
robust optimization plans were compared with traditional PTV
TAB L E 5 ITV perturbed doses D98 (Gy).
D (mm)a (3,0,0) (3,0,0) (0,5,0) (0,5,0) (0,0,3) (0,0,3)
ITV-IMRT 58.57 (52.8–59.8) 58.38 (53.24–59.86) 57.93 (52.82–59.87) 58.18 (54.31–59.58) 58.28 (52.71–59.9) 58.61 (53.4–59.45)
ITV-VMAT 58.25 (52.84–59.95) 57.72 (53.74–59.8) 57.43 (52.82–59.51) 57.94 (53.24–59.12) 57.84 (51.9–59.93) 57.89 (53.72–59.35)
Student t-test
significant?
No P > 0.05 No P > 0.05 Yes P = 0.001 Yes P = 0.012 Yes P = 0.015 Yes P = 0.026
ashifted distance in mm from isocenter in (x, y, z) direction.
TAB L E 6 ITV perturbed doses of D95 (Gy).
D (mm)a (3,0,0) (3,0,0) (0,5,0) (0,5,0) (0,0,3) (0,0,3)
ITV-IMRT 59.52 (56.71–60.07) 59.4 (57.62–60.08) 59.2 (56.41–60.13) 59.19 (56.34–60) 59.47 (58–60.15) 59.4 (57.7–60.26)
ITV-VMAT 59.47 (56.26–60.6) 59.05 (56.71–60.58) 58.85 (55.07–60.28) 58.94 (55.26–59.88) 59.17 (56.84–60.7) 59.18 (58.05–60.35)
Student t-test
significant?
No P > 0.05 No P > 0.05 Yes P < 0.001 Yes P = 0.014 No P > 0.05 No P > 0.05
ashifted distance in mm from isocenter in (x, y, z) direction.
TAB L E 7 Median and ranges of OAR doses (Gy) for robust optimization and PTV margin-based IMRT and VMAT plans
IMRT
Lung
Heart (Dmean dose)
Esophagus
(Dmean dose) Spinal cord (Dmaximum dose)Dmean dose V20 Gy (%) V15 Gy (%)
ITV-IMRTa 3.42 (2.78–10.55) 4.69 (2.54–19.01) 6.58 (3.94–22.47) 1.62 (0.08–11.18) 2.19 (0.78–10.29) 10.26 (1.12–18.88)
PTV-IMRTb 4.54 (3.14–12.80) 5.66 (3.15–20.6) 8.19 (5.18–23.96) 2.02 (0.08–13.44) 2.89 (0.94–12.06) 12.56 (1.56–21.59)
ANOVA t-test
significant?
Yes P < 0.001 Yes P < 0.001 Yes P < 0.001 Yes P = 0.002 Yes P < 0.001 Yes P < 0.001
VMAT Lung Heart (Dmean dose) Esophagus
(Dmean dose)
Spinal cord
(Dmaximum dose)
Dmean(Gy) V20 Gy (%) V37 (%)
ITV-VMATa 3.6 (2.59–10.59) 4.6 (2.65–18.49) 6.78 (4.06–22.14) 1.60 (0.08–12.25) 1.91 (0.7–10.53) 9.39 (1.36–22.29)
PTV-VMATb 4.49 (3.08–12.83) 6.18 (3.29–20.37) 8.75 (4.89–24.01) 1.93 (0.10–14.64) 2.61 (0.86–11.61) 11.40 (1.69–23.95)
ANOVA t-test
significant?
Yes P < 0.001 Yes P < 0.001 Yes P < 0.001 Yes P = 0.003 Yes P = 0.006 Yes P < 0.001
aITV-based robust optimization plans.
bPTV margin-based optimization plans.
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margin-based treatment plans for ITV dose coverage, HI, CI, MU and
OAR doses. Instead of traditionally representing the target region
using PTV, the setup and target position uncertainties were entered
into the treatment planning system and optimized concomitantly
with the dose optimization using the minimax optimization method.
There are several important factors that can contribute to the
deviation between planned and delivered dose. These factors include
organ motion, geometrical uncertainties during target delineation and
random/systematic errors during positioning and treatment.13 Organ
motion and geometrical uncertainties will directly affect the defini-
tion of ITVs. Generally there are two methods to generate ITV; one
is to manually contour GTV using ten selected phases of 4DCT data-
sets; the other is to generate an ITV contour based on the maximum
intensity projections (MIP) that was automatically generated from
4DCT simulation. The former method is time consuming and requires
more physician time. However, the latter was reported to produce
smaller ITV volumes compared to the ten-phase manually contouring
method.14 Therefore in this study, we decided to use the former
method to define ITV, with the additional benefit of obtaining dose
distributions in each phase of the respiratory cycle. The ten-phase
manually contouring method is not very practical for the routine
clinic performance. The simplified ITV contouring method needs to
be developed such as using MIP plus two more image datasets (the
full inspiration and expiration phases of the respiratory cycle). How-
ever, this proposed method need to be verified and it is beyond the
scope of this study. For each patient, ten robust optimization treat-
ment plans were generated corresponding to each of the ten-phase
image datasets. Differences were found in ITV dose distributions for
both IMRT and VMAT treatment plans. Figs. 2 and 3 show an exam-
ple of two patients’ ITV DVHs, whereas Fig. 2 shows the ten-phase
DVHs for one patient with the largest tumor motion among all 20
patients in this study. Figure 3 shows ten-phases DVHs for the
patient with the smallest target motion. It was noticed that the ten-
phase ITV dose distributions were more widely spatially distributed
for the patients with larger tumor motions, while they almost over-
lapped with each other for patients with smaller tumor motions.
In comparing robust and nonrobust optimization plans, robust
optimization plans had better ITV dose coverage, better CI, and
worse HI compared to corresponding PTV margin-based plans
(Table 2 & Fig. 1) for both IMRT and VMAT techniques. This study
showed that PTV margin-based plans had higher mean doses and
R95, with R95 values all larger than 1.0. The worse CI values in PTV
margin-based plans could be caused by larger TVPIV (the target vol-
ume covered by the prescription isodose volume), which decreases
the plan conformity. It was also noticed that PTV margin-based
plans had greater variations in Dmean and R95 compared to robust-
TAB L E 8 Median and ranges of OAR doses (Gy) from robust optimization IMRT and VMAT plans.
Lung
Heart (Dmean dose) Esophagus (Dmean dose)
Spinal cord
(Dmaximum dose)
Dmean dose V20 Gy (%) V37 (%)
ITV-IMRT 3.42 (2.78–10.55) 4.69 (2.54–19.01) 6.58 (3.94–22.47) 1.62 (0.08–11.18) 2.19 (0.78–10.29) 10.26 (1.12–18.88)
ITV-VMAT 3.6 (2.59–10.59) 4.60 (2.65–18.49) 6.78 (4.06–22.14) 1.60 (0.08–12.25) 1.91 (0.7–10.53) 9.39 (1.36–22.29)
Student t-test
significant?
No P > 0.05 No P > 0.05 No P > 0.05 No P > 0.05 No P > 0.05 No P > 0.05
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F I G . 2 . Example of target DVHs from ITV-IMRT and ITV-VMAT plans generated from ten respiratory phases (Pt5, max target motion
d = 3.4 cm, ITV = 28.03 cc).
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optimized plans. This could be explained by the following reasons:
robust optimization use minimax optimization method to minimize
the objective function, so the planning target volume tends to be
smaller compared to the traditional PTV margin-based planning tar-
get volume. In addition, when the planning target is large in size or
adjacent to the surrounding critical organs (i.e., chest wall), it is
more difficult for PTV margin-based plan to reduce the critical tar-
get dose (chest wall or normal lung tissue) to an acceptable level.
So PTV margin-based plans might be compromised more which
may result in a larger range of Dmean and R95 compared to robust-
optimized plan.
In robust optimization, a minimal margin is applied to the tar-
get.15 Therefore, it is also important to confirm adequate target
dose coverage in evaluating plan robustness. This is even more
important in moving targets. Perturbed dose was computed to eval-
uate plan robustness by specifying a shift from the isocenter in (LR,
IS, AP) directions. Currently, there is no standard for perturbed dose
computation. The shifted values used (3 mm, 5 mm, 3 mm) in
this study were based on empirical data from other published stud-
ies 16,17 and from our clinical experience. Perturbed doses of D99,
D98, and D95 were computed for all robust optimization plans and
results showed that D99≥95% of Dp, D98≥96.6% of Dp, and
D95≥98% of Dp. A Student t-test showed that the ITV dose cover-
age was worse for ITV-VMAT plans compared to ITV-IMRT plans in
terms of D99 and D98. For perturbed dose of D95, no difference
was found between ITV-VMAT and ITV-IMRT plans except for D95
in IS direction. This might indicate that VMAT plans are more sensi-
tive for off isocenter uncertainty compared to IMRT plans.
Robust optimization plans spared more of the OAR doses includ-
ing lung, chest wall, heart, esophagus, and maximum cord doses
compared to PTV margin-based plans (Table 7). The robust optimiza-
tion plans have the advantage of finding the best scenario for the
trade-off between target coverage robustness and OAR sparing. This
is important for those critical organs located near the target. For
example, it was observed that 8 of 20 patients for PTV margin-based
plans, the chest wall doses were above the constraint dose (at most
5 cc of the chest wall volume received 5 Gy)10 in this study,
whereas all the chest wall doses calculated from robust optimization
plans were within this dose–volume limit. Figure 4 shows an exam-
ple of isodose distribution from a robust optimization plan (a) and
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F I G . 3 . Example of target DVHs from ITV-IMRT and ITV-VMAT plans generated from ten respiratory phases (Pt8, max target motion
d = 1 cm, ITV = 3.29 cc).
F I G . 4 . Isodose distribution from robust
optimization IMRT and PTV margin-based
IMRT plans. (a: robust optimization ITV-
IMRT plan;
b: PTV margin-based PTV-IMRT plan)
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from a PTV margin-based plan (b) for one of the selected patients
whose tumor target was located near the chest wall.
Archibald-Heeren et al. 18 reported that tumors with large
motion and large density variations in surrounding tissue may result
in significant improvements in dose stability with robust optimization,
whereas for smaller tumor motion of <1 cm, the effect was less sig-
nificant. However, no correlation was found between ITV mean dose
and tumor site/tumor size/tumor motion in this study. To subgroup
the patients by tumor size, tumor location or tumor motion extent,
more patient data might be needed to obtain meaningful statistical
results. One last finding in this study was that PTV margin-based
plans delivered more MU compared to robust optimization plan. The
median MU for PTV margin-based plans was 479 MU (PTV-IMRT)
and 303 MU (PTV-VMAT) higher compared to corresponding robust
optimization plans (Table 2). This reduced number of MUs in robust
optimization planning could translate into less treatment time, possi-
bly less respiratory motion cycles during treatment.
5 | CONCLUSION
Robust optimization plans provide robust target coverage for both
ITV-IMRT and ITV-VMAT plans. The plan robustness was evaluated
with perturbed doses by specifying a user defined shifted values
from isocenter to 3 mm in LR, 5 mm in IS, and 3 mm in AP
directions. The perturbed doses of D99, D98, and D95 were all satis-
fied at least 99% of the ITV to receive 95% of the prescription
doses. In addition, better ITV dose coverage, better CI, and worse HI
were found compared to PTV margin-based plans. OAR doses were
compared and the results showed that robust optimization plans
have significantly reduced OAR doses especially for normal lung
doses and OAR doses adjacent to the lung lesions. It was also
observed that PTV margin-based plans had higher MU compared to
robust optimization plans.
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